We pre\~iously reported the results of 29 relapsed and 31 non-relapsed cases of node-negative breast cancer studied for HER-2/neu oncogene amplification m g FISH and the Vysis HER-2/neu and chromosome 17 control probes (Vysis, Downers Grove, 1L). Prevlous research performed in this laboratory on HER-2/neu amplification m stages I to IV breast cancer indicated that the most aggressive dlsease stages were associated with the higher frequency of oncogene amplification and the highest level of amplification. These data support the hypothesis that HER-2/neu is a prognostic marker of poor outcome. Thus, a retrospective study of HER-2 / m amplification in relapsed and non-relapsed node-negative breast cancer was initiated to explore further the above question. Out of a total of 46 relapsed cases studied, 13 (28.3%) were found to be amplified. The corresponding frequency of aniplification for the controls was 4 (8.7%) of 46 non-relapsed cases. The difference was statistically significant with a p value of ~0 . 0 5 . Although these results st111 need to be confmned and extended m other centers, they are quite remarkable and suggest an association between HER-?/neu amplification and disease relapse In patients with node-negatlve breast cancer. Our results also demonstrate that FlSH IS a sensitive technique for studymg oncogene amplification in archival pathological specimens.
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We pre\~iously reported the results of 29 relapsed and 31 non-relapsed cases of node-negative breast cancer studied for HER-2/neu oncogene amplification m g FISH and the Vysis HER-2/neu and chromosome 17 control probes (Vysis, Downers Grove, 1L). Prevlous research performed in this laboratory on HER-2/neu amplification m stages I to IV breast cancer indicated that the most aggressive dlsease stages were associated with the higher frequency of oncogene amplification and the highest level of amplification. These data support the hypothesis that HER-2/neu is a prognostic marker of poor outcome. Thus, a retrospective study of HER-2 / m amplification in relapsed and non-relapsed node-negative breast cancer was initiated to explore further the above question. Out of a total of 46 relapsed cases studied, 13 (28.3%) were found to be amplified. The corresponding frequency of aniplification for the controls was 4 (8.7%) of 46 non-relapsed cases. The difference was statistically significant with a p value of ~0 . 0 5 . Although these results st111 need to be confmned and extended m other centers, they are quite remarkable and suggest an association between HER-?/neu amplification and disease relapse In Oncogene amplification is a manifestation of genetic instability, which has been implicated in the pathogenesis of many cancers. Work performed in this laboratory has focused on HER-2/neu amplification in breast cancer, ovarian cancer, cervical cancer and rhabdomyosarcoma, a l l of which revealed HER-2/neu amplification in at least a proportion of tumors. In the present project, we studied HER-2/neu oncogene amplification in prostate carcinoma, 244,000 new cases of which are diagnosed yearly, and which affects a significant number of men. Fluorescent rn situ hybridization (FISH) using the Vysis HER-2/neu probe with a chromosome 17 centromere control probe was performed m formal~n-flxed paraffin-embedded archival prostate cancer tissues. Out of a total of 85 cases studied, 7 cases (8.2%) were found to be amplified. Of those 7 ampllfled cases, 2 were also h-isomic for chromosome 17. Amplification is d e f i e d as a signal ratio of HER-2/neu to chromosome 17 of 21.5, after Mark et al. (1998) . Cl~nicopatholog~c characteristics of t h e amplified cases versus the nonamplified cases will be compared. Although the results of the present study still need to be confirmed and extended by additional cases in other centers, the data thus far do indicate that a small subset of prostate cancer is characterized by HER-2 / n e u p amplification, as in other cancers. (This study was partially funded by Vysis, Inc., Downers Grove, IL).
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